

Applicants submit herewith a substitute Sequence Listing in computer and paper form in accordance with 37 C.F.R. §1.821-1.825. The content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821(c) and (e) are the same and do not include new matter. Also enclosed is a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

Applicants respectfully request consideration of the following amendments.

IN THE CLAIMS

Please **amend** the claims as follows:

Rule 129 ~~887~~ (Amended) An isolated and purified peptide having an amino acid sequence KXaa₍₃₎TXaaQEXaaD (SEQ ID NO: 13) wherein said peptide does not have toxin agonist activity, wherein Xaa is an amino acid.

Rule 129 ~~88~~ ⁸⁹ (Amended) An isolated and purified peptide having an amino acid sequence KXaa₍₆₎LD (SEQ ID NO: 14) wherein said peptide does not have toxin agonist activity, wherein Xaa is an amino acid.

E ~~89~~ ⁹⁰ (Amended) An isolated an purified peptide having an amino acid sequence charged amino acid-Xaa₍₂₎-hydrophobic amino acid-X-hydrophobic amino acid-polar amino acid-polar amino acid-hydrophobic amino acid-D (SEQ ID NO: 15), wherein said peptide does not have toxin agonist activity, and wherein Xaa is an amino acid.

91 ~~90~~ (Amended) An isolated and purified peptide having an amino acid sequence Xaa₍₂₎KXaa₍₃₎TXaaQEXaaD (SEQ ID NO: 16) wherein said peptide does not have toxin agonist activity, wherein Xaa is an amino acid.